CollPlant Biotechnologies files prospectus for 31.047M share offering

0 min read Updated on 10 Jul 2026, 04:43 AM

Reviewed by

Riya DScanX News Team

AI Summary

CollPlant Biotechnologies filed a prospectus for an offering of 31.047M shares on behalf of selling shareholders. The filing was submitted to the SEC.

*this image is generated using AI for illustrative purposes only.

CollPlant Biotechnologies filed a prospectus for an offering of 31.047M shares on behalf of selling shareholders. The filing was submitted to the SEC.

The prospectus outlines the details of the share offering, which is being conducted on behalf of selling shareholders. The total number of shares offered is 31.047M.

Filing Details

The prospectus was filed with the SEC and is available for public review. The document provides comprehensive information regarding the offering.

Metric	Details
Total Shares Offered	31.047M
Filing Entity	CollPlant Biotechnologies
Regulatory Body	SEC

How will this large secondary offering impact CollPlant's stock price and market liquidity?

Who are the selling shareholders, and what does their exit suggest about the company's future prospects?

What are the intended uses of the proceeds from this offering, if any, and how might they influence CollPlant's growth strategy?

Read Next Article

CollPlant Biotechnologies launches $2.6M offering of shares and warrants

1 min read Updated on 30 Jun 2026, 06:36 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

CollPlant Biotechnologies has launched a private placement to issue 7,647,061 ordinary shares along with series A and series B warrants, aiming to raise approximately $2.6 million in gross proceeds. The securities are priced at $0.34 per share, with warrants exercisable upon shareholder approval and expiring two to five years post-registration. The company plans to use the net proceeds for working capital, research and development, and evaluating strategic business combinations.

*this image is generated using AI for illustrative purposes only.

CollPlant Biotechnologies has commenced a private placement offering to raise approximately $2.6 million in gross proceeds through the sale of ordinary shares and accompanying warrants. The regenerative and aesthetics medicine company entered into a definitive agreement to issue and sell an aggregate of 7,647,061 ordinary shares. The offering also includes unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares.

The securities are being offered at a combined purchase price of $0.34 per ordinary share and accompanying warrants. Both series A and series B warrants carry an exercise price of $0.34 per share. The warrants become exercisable upon the Shareholder Approval Date. Series A warrants are set to expire two years after the effective date of a registration statement, while series B warrants will expire five years after the effective date of the registration statement.

The private placement is expected to close on or about July 1, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds of approximately $2.6 million are calculated before deducting the placement agent's fees and other related expenses payable by the company.

CollPlant intends to utilize the net proceeds from this offering for general corporate purposes. The allocation of funds includes supporting working capital and funding its research and development programs. Additionally, the company plans to continue evaluating strategic business combinations, which may encompass potential acquisitions, joint ventures, and other strategic transactions.